These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 9860067

  • 1. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [Abstract] [Full Text] [Related]

  • 2. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I, Mamiya K, Urae A, Wada Y, Kimura M, Irie S, Amamoto T, Kubota T, Yoshioka S, Nakamura K, Nakano S, Tashiro N, Higuchi S.
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K.
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [Abstract] [Full Text] [Related]

  • 4. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [Abstract] [Full Text] [Related]

  • 5. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
    Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA, Kato R, Yamazoe Y.
    Biochem Pharmacol; 1999 Jun 01; 57(11):1297-303. PubMed ID: 10230773
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, Nakagawa K.
    Ther Drug Monit; 2007 Feb 01; 29(1):118-21. PubMed ID: 17304159
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC, Gala JL, Horsmans Y.
    Pharmacogenet Genomics; 2005 Nov 01; 15(11):779-86. PubMed ID: 16220110
    [Abstract] [Full Text] [Related]

  • 13. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H, Shimada T.
    Arch Biochem Biophys; 1997 Oct 01; 346(1):161-9. PubMed ID: 9328296
    [Abstract] [Full Text] [Related]

  • 14. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ, Yen MF, Hu OY, Lin MS, Hsiong CH, Hung CC, Liou HH.
    Pharmacotherapy; 2008 Jan 01; 28(1):35-41. PubMed ID: 18154472
    [Abstract] [Full Text] [Related]

  • 15. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y, Yang JF, Qi XL, Wang YQ, Wang WZ, Chen B.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 17; 84(20):1686-9. PubMed ID: 15569425
    [Abstract] [Full Text] [Related]

  • 16. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T.
    Biochem Pharmacol; 1998 Jul 15; 56(2):243-51. PubMed ID: 9698079
    [Abstract] [Full Text] [Related]

  • 17. [Genetic polymorphism of the CYP2C subfamily].
    Chiba K.
    Nihon Yakurigaku Zasshi; 1998 Jul 15; 112(1):15-21. PubMed ID: 9755458
    [Abstract] [Full Text] [Related]

  • 18. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H.
    Pharmacogenetics; 1998 Oct 15; 8(5):365-73. PubMed ID: 9825828
    [Abstract] [Full Text] [Related]

  • 19. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J, Steijns LS, van Weelden MJ, de Haan K.
    Pharmacogenetics; 2001 Jun 15; 11(4):287-91. PubMed ID: 11434505
    [Abstract] [Full Text] [Related]

  • 20. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG.
    Pharmacogenetics; 2002 Mar 15; 12(2):111-9. PubMed ID: 11875365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.